Tag: development

CALGARY, Alberta, July 02, 2025 (GLOBE NEWSWIRE) -- NuVista Energy Ltd. (TSX:NVA, "NVA" or "NuVista") is providing revised guidance to our annual production volumes and reiterating our commitment to our shareholder return strategy. Due to continued delays in commissioning the Pipestone Gas Plant (“Pipestone Plant”) and additional required work discovered during a gas plant turnaround in the greater Wapiti area (“Wapiti Turnaround”), we now anticipate annual volumes to average approximately 83,000 Boe/d⁽¹⁾. The impact of the delays due to the Pipestone Plant and Wapiti Turnaround on annual production volumes is approximately 3,500 Boe/d and 6,000 Boe/d, respectively. Both third-party facilities are expected to be fully operational prior to September.

BOSTON, July 02, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (Nasdaq: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that on July 1, 2025, the Compensation Committee of Praxis’ Board of Directors granted restricted stock unit awards covering an aggregate of 2,100 shares of its common stock to three new non-executive employees under the Praxis Precision Medicines, Inc. 2024 Inducement Plan (the 2024 Inducement Plan). The restricted stock unit awards were granted as inducements material to the employees’ entering into employment with Praxis in accordance with Nasdaq Listing Rule 5635(c)(4).

AURORA, Ontario, July 02, 2025 (GLOBE NEWSWIRE) -- Magna International Inc. (TSX:MG) (NYSE:MGA) 

SAN FRANCISCO, July 02, 2025 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today announced that the Company granted stock options to four new employees to purchase an aggregate of 154,500 shares of the Company's common stock, effective as of July 1, 2025. These awards were approved by the Compensation Committee of Olema’s Board of Directors and granted under the Company's 2022 Inducement Plan as an inducement material to the new employees entering into employment with Olema, in accordance with Nasdaq Listing Rule 5635(c)(4).